Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Xueling Wu,Zhi Yong Yang,Yuxing Li,Carl Magnus Hogerkorp,William R. Schief,Michael S. Seaman,Tongqing Zhou,Stephen D. Schmidt,Lan Wu,Ling Xu,Nancy S. Longo,Krisha McKee,Sijy O'Dell,Mark K. Louder,Diane Wycuff,Yu Feng,Martha Nason,Nicole A. Doria-Rose,Mark Connors,Peter D. Kwong,Mario Roederer,Richard T. Wyatt,Gary J. Nabel,John R. Mascola +23 more
Reads0
Chats0
TLDR
Three broadly neutralizing antibodies are identified, isolated from an HIV-1–infected individual, that exhibited great breadth and potency of neutralization and were specific for the co-receptor CD4-binding site of the glycoprotein 120 (gp120), part of the viral Env spike.Abstract:
Cross-reactive neutralizing antibodies (NAbs) are found in the sera of many HIV-1-infected individuals, but the virologic basis of their neutralization remains poorly understood. We used knowledge of HIV-1 envelope structure to develop antigenically resurfaced glycoproteins specific for the structurally conserved site of initial CD4 receptor binding. These probes were used to identify sera with NAbs to the CD4-binding site (CD4bs) and to isolate individual B cells from such an HIV-1-infected donor. By expressing immunoglobulin genes from individual cells, we identified three monoclonal antibodies, including a pair of somatic variants that neutralized over 90% of circulating HIV-1 isolates. Exceptionally broad HIV-1 neutralization can be achieved with individual antibodies targeted to the functionally conserved CD4bs of glycoprotein 120, an important insight for future HIV-1 vaccine design.read more
Citations
More filters
Journal ArticleDOI
Factors in B cell competition and immunodominance.
TL;DR: This review will focus on recent advances in understanding the roles of B cell precursor frequency, B cell receptor affinity for antigen, antigen avidity, and other factors that can substantially alter the outcomes of Bcell responses to complex antigens.
Journal ArticleDOI
Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies
Thach H. Chu,Andrew R. Crowley,Iara M. Backes,Cheryl H. Chang,Matthew Zirui Tay,Thomas Broge,Marina Tuyishime,Guido Ferrari,Michael S. Seaman,Simone I. Richardson,Georgia D. Tomaras,Galit Alter,David A. Leib,Margaret E. Ackerman +13 more
TL;DR: Results suggest that when high phagocytic activity is desirable, therapeutic antibodies may benefit from being formatted as human IgG3 or engineered IgG1 forms with elongated hinges.
Journal ArticleDOI
Drift of the HIV-1 Envelope Glycoprotein gp120 toward Increased Neutralization Resistance over the Course of the Epidemic: a Comprehensive Study Using the Most Potent and Broadly Neutralizing Monoclonal Antibodies
Mélanie Bouvin-Pley,Marion Morgand,Laurence Meyer,Cécile Goujard,Alain Moreau,Hugo Mouquet,Michel C. Nussenzweig,Craig S. Pace,David D. Ho,Pamela J. Bjorkman,Daniel Baty,Patrick Chames,Marie Pancera,Peter D. Kwong,Pascal Poignard,Pascal Poignard,Francis Barin,Martine Braibant +17 more
TL;DR: A drift of HIV-1 clade B variants over 2 decades toward higher resistance to bNAbs targeting almost all the identified gp120-neutralizing epitopes is confirmed, suggesting a selective pressure on gp120 preferentially.
Journal ArticleDOI
A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations.
Qiao Wang,Eleftherios Michailidis,Yingpu Yu,Zijun Wang,Arlene Hurley,Deena A. Oren,Christian T. Mayer,Anna Gazumyan,Zhenmi Liu,Yunjiao Zhou,Till Schoofs,Kai-Hui Yao,Jan P. Nieke,Jianbo Wu,Qingling Jiang,Chenhui Zou,Chenhui Zou,Mohanmmad Kabbani,Corrine Quirk,Thiago Y. Oliveira,Kalsang Chhosphel,Qianqian Zhang,William M. Schneider,Cyprien Jahan,Tianlei Ying,Jill Horowitz,Marina Caskey,Mila Jankovic,Davide F. Robbiani,Yumei Wen,Ype P. de Jong,Ype P. de Jong,Charles M. Rice,Michel C. Nussenzweig,Michel C. Nussenzweig +34 more
TL;DR: The co-crystal structure of one of the bNAbs with an HBsAg peptide epitope revealed a stabilized hairpin loop, which contains residues frequently mutated in clinical immune escape variants, provides a molecular explanation for why immunotherapy for HBV infection may require combinations of complementary bNABS.
Journal ArticleDOI
Prospects for an HIV vaccine: leading B cells down the right path.
TL;DR: These studies, which used state-of-the-art high-throughput techniques to collectively describe hundreds of new potent and broad HIV-neutralizing antibodies isolated from HIV-infected individuals, are reviewed.
References
More filters
Journal ArticleDOI
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
Peter D. Kwong,Richard T. Wyatt,James E. Robinson,Raymond W. Sweet,Joseph Sodroski,Wayne A. Hendrickson,Wayne A. Hendrickson +6 more
TL;DR: The structure reveals a cavity-laden CD4–gp120 interface, a conserved binding site for the chemokine receptor, evidence for a conformational change upon CD4 binding, the nature of a CD4-induced antibody epitope, and specific mechanisms for immune evasion.
Journal ArticleDOI
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
Brandon F. Keele,Elena E. Giorgi,Elena E. Giorgi,Jesus F. Salazar-Gonzalez,Julie M. Decker,Kimmy T. Pham,Maria G. Salazar,Chuanxi Sun,Truman Grayson,Shuyi Wang,Hui Li,Xiping Wei,Chunlai Jiang,Jennifer L. Kirchherr,Feng Gao,Jeffery A. Anderson,Li Hua Ping,Ronald Swanstrom,Georgia D. Tomaras,William A. Blattner,Paul A. Goepfert,J. Michael Kilby,Michael S. Saag,Eric Delwart,Michael P. Busch,Myron S. Cohen,David C. Montefiori,Barton F. Haynes,Brian Gaschen,Gayathri Athreya,Ha Y. Lee,Natasha T. Wood,Cathal Seoighe,Alan S. Perelson,Tanmoy Bhattacharya,Tanmoy Bhattacharya,Bette T. Korber,Bette T. Korber,Beatrice H. Hahn,George M. Shaw +39 more
TL;DR: A mathematical model of random viral evolution and phylogenetic tree construction is developed and used to analyze 3,449 complete env sequences derived by single genome amplification from 102 subjects with acute HIV-1 (clade B) infection, suggesting a finite window of potential vulnerability of HIV- 1 to vaccine-elicited immune responses, although phenotypic properties of transmitted Envs pose a formidable defense.
Journal ArticleDOI
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.
Laura M. Walker,Sanjay Phogat,Po-Ying Chan-Hui,Denise Wagner,Pham Phung,Julie L. Goss,Terri Wrin,Melissa Simek,Steven P. Fling,Jennifer L. Mitcham,Jennifer Lehrman,Frances Priddy,Ole A. Olsen,Steven Frey,Phillip W. Hammond,Protocol G. Principal Investigators,Stephen M. Kaminsky,Timothy J. Zamb,Matthew Moyle,Wayne C. Koff,Pascal Poignard,Dennis R. Burton,Dennis R. Burton +22 more
TL;DR: High-throughput screening has revealed two new broadly neutralizing antibodies from a clade A–infected donor in Africa, which exhibit great potency and are able to neutralize a wide range of viruses from many different clades.
Journal ArticleDOI
Design of a Novel Globular Protein Fold with Atomic-Level Accuracy
TL;DR: A general computational strategy that iterates between sequence design and structure prediction to design a 93-residue α/β protein called Top7 with a novel sequence and topology, found experimentally to be folded and extremely stable.
Journal ArticleDOI
The antigenic structure of the HIV gp120 envelope glycoprotein
Richard T. Wyatt,Peter D. Kwong,Elizabeth Desjardins,Raymond W. Sweet,James E. Robinson,Wayne A. Hendrickson,Joseph Sodroski +6 more
TL;DR: The spatial organization of conserved neutralization epitopes on gp120 is described, using epitope maps in conjunction with the X-ray crystal structure of a ternary complex that includes a gp120 core, CD4 and a neutralizing antibody.
Related Papers (5)
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.
Laura M. Walker,Sanjay Phogat,Po-Ying Chan-Hui,Denise Wagner,Pham Phung,Julie L. Goss,Terri Wrin,Melissa Simek,Steven P. Fling,Jennifer L. Mitcham,Jennifer Lehrman,Frances Priddy,Ole A. Olsen,Steven Frey,Phillip W. Hammond,Protocol G. Principal Investigators,Stephen M. Kaminsky,Timothy J. Zamb,Matthew Moyle,Wayne C. Koff,Pascal Poignard,Dennis R. Burton,Dennis R. Burton +22 more
Broad neutralization coverage of HIV by multiple highly potent antibodies
Laura M. Walker,Michael Huber,Michael Huber,Katie J. Doores,Katie J. Doores,Emilia Falkowska,Emilia Falkowska,Robert Pejchal,Jean-Philippe Julien,Sheng-Kai Wang,Alejandra Ramos,Po-Ying Chan-Hui,Matthew Moyle,Jennifer L. Mitcham,Phillip W. Hammond,Ole A. Olsen,Pham Phung,Steven P. Fling,Chi-Huey Wong,Sanjay Phogat,Terri Wrin,Melissa Simek,Protocol G. Principal Investigators,Wayne C. Koff,Ian A. Wilson,Dennis R. Burton,Dennis R. Burton,Pascal Poignard,Pascal Poignard +28 more
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding.
Johannes F. Scheid,Hugo Mouquet,Beatrix Ueberheide,Ron Diskin,Florian Klein,Thiago Y. Oliveira,John Pietzsch,John Pietzsch,David Fenyö,Alexander Abadir,Klara Velinzon,Arlene Hurley,Sunnie Myung,Farid Boulad,Pascal Poignard,Pascal Poignard,Dennis R. Burton,Dennis R. Burton,Florencia Pereyra,Florencia Pereyra,David D. Ho,Bruce D. Walker,Bruce D. Walker,Bruce D. Walker,Michael S. Seaman,Pamela J. Bjorkman,Pamela J. Bjorkman,Brian T. Chait,Michel C. Nussenzweig,Michel C. Nussenzweig +29 more
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Supachai Rerks-Ngarm,Punnee Pitisuttithum,Sorachai Nitayaphan,Jaranit Kaewkungwal,Joseph Chiu,Robert Paris,Nakorn Premsri,Chawetsan Namwat,Mark de Souza,Elizabeth Adams,Michael Benenson,Sanjay Gurunathan,Jim Tartaglia,John G. McNeil,Donald P. Francis,Donald Stablein,Deborah L. Birx,Supamit Chunsuttiwat,Chirasak Khamboonruang,Prasert Thongcharoen,Merlin L. Robb,Nelson L. Michael,Prayura Kunasol,Jerome H. Kim +23 more